Researchers aimed to provide a starting point for future research into how gaslighting may present itself, what contributes to its occurrence and how to mitigate its impacts while considering the perspectives of both patients and providers.
Researchers found that injectable naltrexone had the fewest reported GI and liver-related side effects compared to the other drugs.
Study reveals higher gut levels of Blastocystis in people who have better cardiometabolic health and a healthier diet.
Investigating the impact of long-term proton pump inhibitor use.
Results warrant additional studies into the health benefits of aspirin for patients with metabolic dysfunction–associated steatotic liver disease.
Andrew T. Chan, MD, MPH, Director of Epidemiology for the Mass General Cancer Center, and a gastroenterologist focused on cancer prevention among families at high risk of gastrointestinal cancer is working to find out. Chan is co-leading the global team known as PROSPECT, which received a grant of up to $25m over five years, to study early-onset colorectal cancer from Cancer Grand Challenges after an international competition.
In a nationally representative of US adults with self-reported chronic liver disease (CLD), approximately 308,000 (6%) identified delaying medical care due to transportation barriers.
Michael Dougan, MD, PhD, is a senior author of a new study in Clinical Gastroenterology and Hepatology, Tofacitinib Is Effective in Treating Refractory Immune Checkpoint Inhibitor Hepatitis.
Blocking reductive stress in the liver may benefit people with conditions such as obesity and fatty liver disease.
Mass General Cancer Center investigators found that nine percent of esophageal adenocarcinoma patients harbor mutations in cancer-predisposing genes, shedding light on the causes of progression to the disease and new possibilities for screening and treatment.
